Photographers judged AI images for flaws automated checks can miss

Zedge, Inc. (ZDGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029448101ex99-1.htm EARNINGS RELEASE, DATED JUNE 11, 2026, REPORTING THE RESULTS OF OPERATIONS FOR ZEDGE, INC.'S FISCAL QUARTER ENDED APRIL 30, 2026 Exhibit 99.1 Zedge Reports Third Quarter Fiscal 2026 Results Subscription revenue increased 32%, and active subscriptio

Moderna shares dropped 25% after leaked cancer vaccine data, despite positive results. The vaccine, developed with Merck, reduced recurrence or death risk by 42% in melanoma patients. Analysts noted the data was positive but investors had high expectations. Merck shares fell 1%.

SpaceX seeks 80,000 cell sites for Starlink, reportedly in talks with Crown Castle. AT&T, Verizon, and T-Mobile fell on competition concerns, while Crown Castle and American Tower rose.

Moderna and Merck released early phase 3 trial data for their mRNA-based skin cancer vaccine, showing a 42% reduction in recurrence or death risk compared to a single treatment. The trial involved 1,137 high-risk melanoma patients. Both companies plan to seek regulatory approval. Moderna's stock dropped following the announcement.

Nvidia CEO Jensen Huang announced a plan to accelerate AI data center construction, introducing the DSX POD design for rapid deployment. Nvidia claims these centers can be operational in 14 days, significantly reducing setup time. The company reported strong Q2 revenue growth, driven by data center sales. Huang emphasized the financial impact of delays, stating a $50 billion data center could generate $40 billion annually in revenue.

Moderna and Merck reported that their mRNA cancer vaccine, intismeran, reduced death or recurrence risk by 42% in a late-stage melanoma trial. The vaccine, combined with Merck's Keytruda, showed improved recurrence-free and metastasis-free survival rates compared to Keytruda alone. The companies plan to seek regulatory approval and presented the data at a medical conference.